Additional file 2: of Molecular diversity and function of jasmintides from Jasminum sambac

Figure S1. NH/CιH fingerprint region of 2D-NOESY spectrum of jS3 recorded in 90% H2O/10% D2O at 298 K. Sequential connectivity of each amino acid residue are shown by solid lines. (DOCX 4392 kb

Additional file 10: of Molecular diversity and function of jasmintides from Jasminum sambac

Table S4. The amino acid sequences of jasmintide jS3, human β-defensin hBD1 and conotoxin as24a. (DOCX 12 kb

Additional file 3: of Molecular diversity and function of jasmintides from Jasminum sambac

Figure S2. Summary of sequential and medium NOE connectivity. Slowly exchanging amide protons (filled box) and backbone vicinal coupling constants (open circle: 3JHNα < 6 Hz, filled circle: 3JHNα > 8 Hz) are indicated. (DOCX 4739 kb

Additional file 1: of Molecular diversity and function of jasmintides from Jasminum sambac

Table S1. NMR restraints and statistics of the solution structure of jS3. (DOCX 14 kb

Additional file 4: of Molecular diversity and function of jasmintides from Jasminum sambac

Figure S3. NOE cross peak between the Hβs of the each disulfide bond in jS3. (DOCX 171 kb

Additional file 8: of Molecular diversity and function of jasmintides from Jasminum sambac

Figure S6. The effect of jasmintide jS3 on the cell viability of Sf9 cells. (DOCX 111 kb

Additional file 9: of Molecular diversity and function of jasmintides from Jasminum sambac

Table S3. TM align score between jasmintide jS3 and other CRPs with 6 cysteine residues. (DOCX 12 kb

Additional file 6: of Molecular diversity and function of jasmintides from Jasminum sambac

Figure S5. Phylogenetic tree of the 14 jasmintide precursors. The precursors were aligned using Clustal Omega and the tree was constructed with 1000 bootstraps using neighbor-joining algorithm. (DOCX 17 kb

Additional file 1: of Favorable longitudinal change of lung function in patients with asthma-COPD overlap from a COPD cohort

Table S1. The component distribution of ACO. Table S2. Longitudinal change of annual forced expiratory volume in 1 s (mL) in ACO by use of ICS/LABA or ICS during follow up (n = 47). (DOCX 15 kb

Additional file 1: of Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trial

SPIRIT checklist. (DOC 126 kb